Statistik Asas
| LEI | 213800B9N83DSNT33F79 |
| CIK | 1492074 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Abcam Limited
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| February 12, 2024 |
GB:ABCM / Abcam PLC / Durable Capital Partners LP - AMENDMENT TO SC 13G Passive Investment SC 13G/A 1 abcamsc13ga-123123.htm AMENDMENT TO SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 000380204 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| January 12, 2024 |
GB:ABCM / Abcam PLC / HARDING LOEVNER LP - HARDING LOEVNER LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Abcam Plc (Name of Issuer) American Depositary Receipt (Title of Class of Securities) 000380204 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-39633 Abcam Limited (Exact name of registrant as specified in its charte |
|
| December 15, 2023 |
Filed with the Securities and Exchange Commission on December 15, 2023 Filed with the Securities and Exchange Commission on December 15, 2023 Registration No. |
|
| December 15, 2023 |
As filed with the United States Securities and Exchange Commission on December 15, 2023 As filed with the United States Securities and Exchange Commission on December 15, 2023 Registration No. |
|
| December 15, 2023 |
As filed with the United States Securities and Exchange Commission on December 15, 2023 As filed with the United States Securities and Exchange Commission on December 15, 2023 Registration No. |
|
| December 15, 2023 |
As filed with the United States Securities and Exchange Commission on December 15, 2023 As filed with the United States Securities and Exchange Commission on December 15, 2023 Registration No. |
|
| December 8, 2023 |
GB:ABCM / Abcam PLC / HBK INVESTMENTS L P - ABCAM PLC Activist Investment SC 13D/A 1 p23-2944sc13da.htm ABCAM PLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Abcam plc (Name of Issuer) Ordinary shares, nominal value £0.002 per share (Title of Class of Securities) 000380204** (CUSIP Number) Jon L. Mosle HBK Investments L.P. 2300 North Field Street, Suite 2200 Dallas, T |
|
| December 6, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Addr |
|
| December 4, 2023 |
Exhibit 99.1 Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales Cambridge, UK / Waltham, MA, December 4, 2023 – Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address |
|
| November 20, 2023 |
GB:ABCM / Abcam PLC / HBK INVESTMENTS L P - ABCAM PLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Abcam plc (Name of Issuer) Ordinary shares, nominal value £0.002 per share (Title of Class of Securities) 000380204** (CUSIP Number) Jon L. Mosle HBK Investments L.P. 2300 North Field Street, Suite 2200 Dallas, Texas 75201 (214) 758-6107 Eleazer Klein, |
|
| November 20, 2023 |
GB:ABCM / Abcam PLC / HBK INVESTMENTS L P - ABCAM PLC Activist Investment SC 13D/A 1 p23-2858sc13da.htm ABCAM PLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Abcam plc (Name of Issuer) Ordinary shares, nominal value £0.002 per share (Title of Class of Securities) 000380204** (CUSIP Number) Jon L. Mosle HBK Investments L.P. 2300 North Field Street, Suite 2200 Dallas, T |
|
| November 17, 2023 |
EX-99.1 Exhibit 99.1 Abcam Acquisition by Danaher has Received all Identified Clearances; Transaction Expected to Close on December 6, 2023 Cambridge, UK / Waltham, MA, November 17, 2023 – Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its propos |
|
| November 17, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Addr |
|
| November 6, 2023 |
Shareholders of Abcam Approve Proposed Acquisition by Danaher EX-99.1 Exhibit 99.1 Shareholders of Abcam Approve Proposed Acquisition by Danaher Cambridge, UK / Waltham, MA, November 6, 2023 – Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE: DHR) (‘Danahe |
|
| November 6, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Addr |
|
| November 1, 2023 |
GB:ABCM / Abcam PLC / Milner Jonathan - SC 13D/A Activist Investment SC 13D/A 1 tm2329538d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 17)* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securi |
|
| November 1, 2023 |
Statement from Dr. Jonathan Milner on the suspension of the “VOTE AGAINST” campaign Exhibit 99.26 Statement from Dr. Jonathan Milner on the suspension of the “VOTE AGAINST” campaign CAMBRIDGE, England, 1 November 2023 - Jonathan Milner, the founder and one of the largest investors in Abcam plc (“Abcam” or the “Company”) (NYSE: ABCM) with ownership of 6.16% of the Company, today issued the following statement in relation to the proposed acquisition of Abcam by Danaher Corporation |
|
| October 23, 2023 |
EX-99.1 Exhibit 99.1 Leading Independent Proxy Advisor Glass Lewis Joins ISS in Recommending Shareholders Vote “FOR” Danaher Corporation’s Proposed Acquisition of Abcam Both Leading Proxy Advisors ISS and Glass Lewis Acknowledge the Thorough Process Undertaken by the Abcam Board in Reaching an Agreement that Provides a Compelling Premium and Certainty of Value to Abcam Shareholders Cambridge, U.K. |
|
| October 23, 2023 |
EX-99.2 3 d607319dex992.htm EX-99.2 Exhibit 99.2 The Abcam / Danaher Transaction: BE HEARD BY VOTING FOR THE TRANSACTION TODAY TO HELP ENSURE A POSITIVE OUTCOME FOR ALL ABCAM SHAREHOLDERS THAT WOULD DELIVER $24 PER SHARE AT CLOSING Vote FOR a transaction that would safeguard your investment against future risk More information on the transaction, Complete the BLUE and YELLOW including details of h |
|
| October 23, 2023 |
Exhibit 99.25 Jonathan Milner Issues Statement Responding to the Glass Lewis Report Welcomes the Glass Lewis report's observations on the disproportionate rewards for Abcam’s Executive Directors and on the identified issues with peer group valuation strategies Urges Shareholders to continue to Vote AGAINST the current proposed acquisition of Abcam by Danaher CAMBRIDGE, England, 23 October 2023 – J |
|
| October 23, 2023 |
GB:ABCM / Abcam PLC / Milner Jonathan - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 16)* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 000380204 (CUSIP Number) Jonathan Mi |
|
| October 23, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Addre |
|
| October 17, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Addre |
|
| October 17, 2023 |
EX-99.1 Exhibit 99.1 Leading Proxy Advisor, ISS, Recommends Shareholders Vote “FOR” Danaher Corporation’s Proposed Acquisition of Abcam ISS Acknowledges the Thorough Process Undertaken by the Abcam Board in Reaching an Agreement that Provides a Premium and Certainty of Value to Abcam Shareholders Cambridge, U.K. / Waltham, MA, October 17, 2023 – Abcam plc (Nasdaq: ABCM) (‘Abcam,’ the ‘Group’ or th |
|
| October 16, 2023 |
EX-99.24 4 tm2328519d1ex99-24.htm EXHIBIT 99.24 Exhibit 99.24 Jonathan Milner Issues Statement Responding to ISS Report Urges shareholders to disregard the ISS report and continue to Vote AGAINST the current proposed acquisition of Abcam by Danaher CAMBRIDGE, England, 16 October 2023 – Jonathan Milner, the founder and one of the largest shareholders in Abcam plc (“Abcam” or the “Company”) (NYSE: A |
|
| October 16, 2023 |
EX-99.23 3 tm2328519d1ex99-23.htm EXHIBIT 99.23 Exhibit 99.23 Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company CAMBRIDGE, England, 16 October 2023 – Dr. Jonathan Milner, the founder and one of the largest shareholders in Abcam plc (“Abcam” or the “Company”) (NYSE: ABCM) with ownership of 6.16%, today iss |
|
| October 16, 2023 |
Dr Jonathan Milner FOCUS ABCAM EX-99.22 2 tm2328519d1ex99-22.htm EXHIBIT 99.22 Exhibit 99.22 Dr Jonathan Milner FOCUS ABCAM 2 • Activism campaign brought to bring focus to governance, execution and cost control • All have been lacking and have hit company performance • Precipitated review of strategic alternatives including a potential sale • Culminated in $24 per share offer from Danaher which I believe significantly undervalu |
|
| October 16, 2023 |
GB:ABCM / Abcam PLC / HBK INVESTMENTS L P Activist Investment SC 13D 1 p23-2597sc13d.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Abcam plc (Name of Issuer) Ordinary shares, nominal value £0.002 per share (Title of Class of Securities) 000380204** (CUSIP Number) Jon L. Mosle HBK Investments L.P. 2300 North Field Street, Suite 2200 Dallas, Texas 75201 (214) |
|
| October 16, 2023 |
GB:ABCM / Abcam PLC / Milner Jonathan - SC 13D/A Activist Investment SC 13D/A 1 tm2328519d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 15)* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securi |
|
| October 16, 2023 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p23-2597exhibit99.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing add |
|
| October 12, 2023 |
Exhibit 99.1 Independent Directors of Abcam highlight compelling reasons for shareholders to support proposed sale to Danaher Cambridge, U.K. / Waltham, MA, October 12, 2023 – Abcam plc (Nasdaq: ABCM) (‘Abcam,’ the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today filed an investor presentation with the U.S. Securities and Exchange Commission (available |
|
| October 12, 2023 |
Recommended Acquisition of Abcam by Danaher October 2023 Exhibit 99.2 Forward-looking statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” |
|
| October 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address o |
|
| October 12, 2023 |
EX-99.21 2 tm2328270d1ex99-21.htm EXHIBIT 99.21 Exhibit 99.21 MEETING OF SHAREHOLDERS OF Abcam plc Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX United Kingdom (Registered in England & Wales under Company No. 03509322) PROXY STATEMENT SUPPLEMENT DATED October 12, 2023 OF Jonathan Milner To Fellow Abcam Shareholders: This Proxy Statement Supplement (this “Proxy Supplement”) updates |
|
| October 12, 2023 |
GB:ABCM / Abcam PLC / Milner Jonathan - SC 13D/A Activist Investment SC 13D/A 1 tm2328270d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 14)* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securi |
|
| October 10, 2023 |
Exhibit 99.20 Jonathan Milner issues Open Letter to shareholders of Abcam plc Urges shareholders to question the scheme circular, the unacceptable Offer price and continue to Vote AGAINST the current proposed acquisition of Abcam by Danaher Corporation Reiterates a sale at the right price, to Danaher or to another bidder, would not be blocked by Jonathan Milner, provided that it accurately reflect |
|
| October 10, 2023 |
GB:ABCM / Abcam PLC / Milner Jonathan - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 13)* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 000380204 (CUSIP Number) Jonathan Mi |
|
| October 5, 2023 |
Exhibit 99.2 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. THIS DOCUMENT CONTAINS A PROPOSAL WHICH, IF IMPLEMENTED, WILL RESULT IN THE CANCELLATION OF THE LISTING OF ABCAM ADSs ON THE NASDAQ GLOBAL SELECT MARKET. PART II (EXPLANATORY STATEMENT) OF THIS DOCUMENT COMPRISES AN EXPLANATORY STATEMENT IN COMPLIANCE WITH SECTION 897 OF THE COMPANIES ACT 2006. If you are in any doubt a |
|
| October 5, 2023 |
Exhibit 99.3 ATTENDANCE CARD ABCAM PLC – COURT MEETING Monday 6 November 2023 at 2.00 p.m. (U.K. Time) abcam Notice of availability Please note that, depending on your election, a hard copy of the Scheme Circular containing the Notice of Court Meeting may not be enclosed. This document is, however, available on the Company’s website at https://corporate.abcam.com/investors/danaher-abcam Appointing |
|
| October 5, 2023 |
Exhibit 99.4 ATTENDANCE CARD ABCAM PLC – GENERAL MEETING Monday 6 November 2023 at 2.15 p.m. (U.K. Time) abcam Notice of availability Please note that, depending on your election, a hard copy of the Scheme Circular containing the Notice of General Meeting may not be enclosed. This document is, however, available on the Company’s website at https://corporate.abcam.com/investors/danaher-abcam Appoin |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address o |
|
| October 5, 2023 |
Exhibit 99.1 Abcam files and mails Scheme Circular seeking approval of acquisition of Abcam by Danaher for $24.00 per share Cambridge, U.K. / Waltham, MA, October 5, 2023 – Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today filed and mailed a scheme circular (the ‘Scheme Circular‘) in connection with the acquisition |
|
| September 28, 2023 |
EX-99.19 3 tm2327042d1ex99-19.htm EXHIBIT 99.19 Exhibit 99.19 Jonathan Milner issues Open Letter to shareholders of Abcam plc Urges shareholders to Vote AGAINST the proposed acquisition of Abcam by Danaher Corporation CAMBRIDGE, England, 28 September 2023 – Dr. Jonathan Milner, the founder and one of the largest investors in Abcam plc (“Abcam” or the “Company”) (NYSE: ABCM) with ownership of 6.15% |
|
| September 28, 2023 |
GB:ABCM / Abcam PLC / Milner Jonathan - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 12)* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 000380204 (CUSIP Number) Jonathan Mi |
|
| September 28, 2023 |
Exhibit 99.18 MEETING OF SHAREHOLDERS OF Abcam plc Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX United Kingdom (Registered in England & Wales under Company No. 03509322) PROXY STATEMENT DATED September 28, 2023 OF Jonathan Milner To Fellow Abcam Shareholders: This Proxy Statement and the accompanying WHITE Proxy Card are being furnished to shareholders (“Shareholders”) of Ab |
|
| September 15, 2023 |
Abcam plc Statement on Dr. Jonathan Milner’s Announcement Exhibit 99.1 Abcam plc Statement on Dr. Jonathan Milner’s Announcement CAMBRIDGE, England & WALTHAM, Mass., September 14, 2023 – Abcam plc (Nasdaq: ABCM) (“Abcam” or the “Company”), notes today’s announcement by Dr. Jonathan Milner. The Company considers it surprising that Dr. Milner has taken active steps to oppose the deal without reviewing the full details in the Scheme Circular to be published |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address |
|
| September 14, 2023 |
GB:ABCM / Abcam PLC / Milner Jonathan - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 11)* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 000380204 (CUSIP Number) Jonathan Mi |
|
| September 14, 2023 |
Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace Board Exhibit 19.17 Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace Board CAMBRIDGE, England, 14 September 2023 – Dr. Jonathan Milner, the founder and one of the largest investors in Abcam plc (“Abcam” or the “Company”) (NYSE: ABCM) with ownership of 6.14%, today announces his decision to vote against the proposed acquisition of Abcam by Danaher Corporation (NYSE: |
|
| August 31, 2023 |
ABCAM PLC Interim results for the six-month period ended 30 June 2023 Exhibit 99.1 ABCAM PLC Interim results for the six-month period ended 30 June 2023 31 August 2023, Cambridge, UK / Waltham, MA – Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its interim results for the six-month period ended 30 June 2023 (the ‘period’). FINANCIAL PERFORMANCE Six months ended £m, unle |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address of |
|
| August 28, 2023 |
Danaher to acquire Abcam for $24.00 per Share EX-99.2 Exhibit 99.2 Danaher to acquire Abcam for $24.00 per Share Cambridge, UK / Waltham, MA, August 28, 2023 – Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, announced today that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE: DHR) (‘Danaher’) will acquire all of the outstand |
|
| August 28, 2023 |
EX-99.1 Exhibit 99.1 26 August 2023 DANAHER CORPORATION (as Parent) DIADEM HOLDCO LIMITED (as Purchaser) and ABCAM PLC (as Company) TRANSACTION AGREEMENT 99 Bishopsgate London EC2M 3XF United Kingdom Tel: +44.20.7710.1000 www.lw.com CONTENTS Page Clause 1. INTERPRETATION 1 2. TRANSFER OF SCHEME SHARES 15 3. CONSIDERATION 16 4. CONDITIONS 18 5. IMPLEMENTATION OF THE SCHEME 21 6. COMPANY EQUITY PLAN |
|
| August 28, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Addres |
|
| August 16, 2023 |
Dr. Jonathan Milner issues Open Letter to the Board of Abcam PLC EX-99.16 2 tm2323855d1ex99-16.htm EXHIBIT 99.16 Exhibit 99.16 Dr. Jonathan Milner issues Open Letter to the Board of Abcam PLC CAMBRIDGE, England, 16 August 2023 - Dr. Jonathan Milner, the founder and 6.14% shareholder of Abcam PLC (the “Company”), today issued the following letter to the Board of the Company. “It is now approaching two months since Abcam announced the ‘Review of Strategic Alterna |
|
| August 16, 2023 |
GB:ABCM / Abcam PLC / Milner Jonathan - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 10)* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 000380204 (CUSIP Number) Jonathan Mi |
|
| July 12, 2023 |
All Resolutions Withdrawn at Abcam’s EGM Exhibit 99.1 All Resolutions Withdrawn at Abcam’s EGM CAMBRIDGE, England and WALTHAM, Mass., July 12, 2023 – Abcam plc (“Abcam,” “Company,” “Group”) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today held an Extraordinary General Meeting of its shareholders (the “EGM”) that was convened following a requisition notice from Dr. Jonathan Milner dated May 30, 2023 (the |
|
| July 12, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address |
|
| July 5, 2023 |
EX-99.1 Exhibit 99.1 5 July 2023 ABCAM PLC Trading Update Cambridge, UK: Abcam plc (“Abcam,” “Company,” “Group”) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the following preliminary trading update for the half ending 30 June 2023. Preliminary results Period Estimated Reported Revenue Estimated Adjusted Operating Profit % H1 2023 >£203 million >26% |
|
| July 5, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address |
|
| June 28, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address |
|
| June 28, 2023 |
EX-99.1 Exhibit 99.1 Abcam Confirms Dr. Jonathan Milner has Withdrawn EGM Requisition Notice and Related Resolutions Shareholders are encouraged not to attend or submit voting instructions or proxies related to the EGM CAMBRIDGE, England and WALTHAM, Mass., June 28, 2023 – Abcam plc (“Abcam,” “Company,” “Group”) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today co |
|
| June 27, 2023 |
LETTER FROM THE BOARD OF DIRECTORS OF ABCAM PLC Exhibit 99.2 LETTER FROM THE BOARD OF DIRECTORS OF ABCAM PLC June 26, 2023 Dear Shareholders, The Extraordinary General Meeting of Abcam plc (“Abcam”, the “Company,” “Group”), to be held on July 12, 2023, is rapidly approaching, and your vote is critical to optimizing the Company’s value proposition in the short, medium and long term. During the tenures of Chairman, Peter Allen, and CEO, Alan Hirz |
|
| June 27, 2023 |
Exhibit 99.15 Dr. Jonathan Milner Announces Suspension of Proxy Solicitation Will Hold Board Accountable if Strategic Review Fails to Deliver on Company’s Promise CAMBRIDGE, England, 26 June 2023 - Dr. Jonathan Milner, the founder and 6.3% shareholder of Abcam PLC (the “Company”), today issued the following statement regarding the upcoming extraordinary meeting of shareholders of the Company: “In |
|
| June 27, 2023 |
6-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX Un |
|
| June 27, 2023 |
GB:ABCM / Abcam PLC / Milner Jonathan - SC 13D/A Activist Investment SC 13D/A 1 tm2319725d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 9)* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securit |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address of p |
|
| June 26, 2023 |
Exhibit 99.2 Abcam plc Reiterates Strategy and Track Record of Shareholder Value Creation Board of Directors Mails Letter to Shareholders Company announced review of strategic alternatives to maximize shareholder value and hired Lazard and Morgan Stanley to help the Company run the process FY2024 guidance underscores Abcam’s shareholder value proposition and demonstrates the Company is on track to |
|
| June 26, 2023 |
Exhibit 99.1 Abcam plc: FY2024 Guidance Cambridge, UK: Abcam plc (“Abcam,” “Company,” “Group”) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the following updates. Although the Company acknowledges that these financial updates are being provided outside our normal reporting cycles, the Board and management team believe that it is in the best interests |
|
| June 23, 2023 |
ABCAM PLC Abcam Announces Review of Strategic Alternatives EX-99.1 Exhibit 99.1 23 June 2023 ABCAM PLC Abcam Announces Review of Strategic Alternatives Cambridge, UK / Waltham, MA: Abcam plc (“Abcam,” “Company,” “Group”) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today announces that, having listened to and extensively engaged with shareholders, the Board of Directors has unanimously decided to initiate a process to expl |
|
| June 23, 2023 |
GB:ABCM / Abcam PLC / Milner Jonathan - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 8)* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 000380204 (CUSIP Number) Jonathan Mil |
|
| June 23, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address |
|
| June 23, 2023 |
EX-99.14 2 tm2319464d1ex99-14.htm EXHIBIT 99.14 Exhibit 99.14 Jonathan Milner issues Open Letter to shareholders of Abcam plc Highlights Abcam Board’s track record of failing to pursue strategic M&A opportunities and lack of incentive to drive share performance Urges all ADS shareholders to vote ‘FOR’ all of Milner’s proposals on the BLUE proxy card by 10am EST on 6 July 2023 ahead of the Extraord |
|
| June 21, 2023 |
GB:ABCM / Abcam PLC / Milner Jonathan - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 7)* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 000380204 (CUSIP Number) Jonathan Mil |
|
| June 21, 2023 |
Exhibit 99.13 Jonathan Milner issues Open Letter to shareholders of Abcam plc Responds to Company’s assertions in its statement on 20 June 2023 Outlines Abcam’s lack of focus and Milner’s detailed plans to restore the Company’s financials, accountability and executional discipline Urges all ADS shareholders to vote ‘FOR’ all of Milner’s proposals on the BLUE proxy card by 10am EST on 6 July 2023 a |
|
| June 21, 2023 |
Exhibit 99.12 GENERAL MEETING OF SHAREHOLDERS OF Abcam plc Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX United Kingdom (Registered in England & Wales under Company No. 03509322) PROXY STATEMENT SUPPLEMENT DATED JUNE 21, 2023 OF Jonathan Milner EXPLANATORY NOTE This Proxy Statement Supplement (the “Proxy Supplement”) updates the Proxy Statement of Jonathan Milner dated June 5, 2023 |
|
| June 20, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address |
|
| June 20, 2023 |
Exhibit 99.10 June 19, 2023 Via E-Mail and Post Abcam plc Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX United Kingdom [email protected]; [email protected] Attn: Marc Perkins, Company Secretary and General Counsel Re: Second Request for Information Pursuant to §§116 and 811 of the Companies Act of 2006 To Abcam plc: Cadwalader, Wickersham & Taft LLP (“Cadwalader” or |
|
| June 20, 2023 |
ABCAM PLC THIS PROXY IS SOLICITED ON BEHALF OF DR. JONATHAN MILNER EX-99.11 5 tm2319107d1ex99-11.htm EXHIBIT 99.11 Exhibit 99.11 June 19, 2023 VIA EMAIL Latham & Watkins (London) LLP 99 Bishopsgate London EC2M 3XF [email protected] Attn: Robbie McLaren, Esq. Dear Mr. McLaren: We received the Information Circular dated June 16, 2023 (the “Circular”) of your client, Abcam plc (the “Company”), and respond to one of its points on behalf of our client, Dr. Jonatha |
|
| June 20, 2023 |
Exhibit 99.9 June 19, 2023 VIA EMAIL Latham & Watkins (London) LLP 99 Bishopsgate London EC2M 3XF [email protected] Attn: Robbie McLaren, Esq. Dear Mr. McLaren: Enclosed is a copy of our letter to Abcam plc (the “Company”) on behalf of Dr. Jonathan Milner (the “Client”) which is a second request pursuant to Section 116 and 118 of the Companies Act of 2006 (the “Act”) for the Company to deliver |
|
| June 20, 2023 |
Exhibit 99.8 June 19, 2023 VIA EMAIL Latham & Watkins (London) LLP 99 Bishopsgate London EC2M 3XF [email protected] Attn: Robbie McLaren, Esq. Re: July 12, 2023 Extraordinary General Meeting – Voting of Uninstructed ADSs Dear Mr. McLaren: Please confirm that, pursuant to §4.10 of the Company’s Deposit Agreement with Citibank, N.A. dated October 26, 2020 (the “Deposit Agreement”), Abcam plc (th |
|
| June 20, 2023 |
EX-99.1 Exhibit 99.1 20 June 2023 Abcam highlights successful execution of strategic priorities to drive shareholder value Files investor presentation; urges shareholders to vote AGAINST all resolutions at July 12 EGM Under CEO Alan Hirzel’s leadership, Abcam has transformed as a business, created significant value for all stakeholders, and outperformed the market The Company is on track to delive |
|
| June 20, 2023 |
Executing on Strategic Priorities to Drive Long Term Value June 2023 EX-99.2 Exhibit 99.2 Executing on Strategic Priorities to Drive Long Term Value June 2023 Investor Presentation | June 2023 Legal Disclaimer Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-look |
|
| June 20, 2023 |
GB:ABCM / Abcam PLC / Milner Jonathan - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 6)* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 000380204 (CUSIP Number) Jonathan Mil |
|
| June 16, 2023 |
EX-99.1 Exhibit 99.1 Abcam plc files and mails Shareholder Circular calling an Extraordinary General Meeting Highlights progress in delivering on long-term plan and outlines attempts to engage constructively with Dr. Jonathan Milner Asks shareholders to support the Company and vote “AGAINST” all resolutions to be proposed at the EGM CAMBRIDGE, England and WALTHAM, Mass., June 16, 2023 /PRNewswire/ |
|
| June 16, 2023 |
EX-99.2 Exhibit 99.2 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action that you should take, you should immediately consult your stockbroker, bank manager, solicitor, accountant or other independent advisor authorised under the Financial Services and Markets Act 2000. If you have sold or otherwise transferred all of your Abcam plc (the “Comp |
|
| June 16, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address |
|
| June 12, 2023 |
GB:ABCM / Abcam PLC / Milner Jonathan - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 5)* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 000380204 (CUSIP Number) Jonathan Mil |
|
| June 12, 2023 |
Exhibit 99.7 Jonathan Milner issues Open Letter to shareholders of Abcam plc Highlights Company’s loss of focus on governance, execution and cost control leading to value destruction and a share price materially below where it should be Outlines Milner’s plan to restore shareholder trust and value and make Abcam the world leading antibody company once again CAMBRIDGE, England, 12 June 2023 – Jonat |
|
| June 12, 2023 |
Abcam in Focus Jonathan Milner Private and Confidential www.abcamfocus.com June 2023 Exhibit 99.6 Abcam in Focus Jonathan Milner Private and Confidential www.abcamfocus.com June 2023 Disclaimer 2 This document has been prepared by and on behalf of Dr. Jonathan Milner (Dr. Milner). Dr. Milner is providing this document for informational and discussion purposes only. The views expressed herein reflect the opinions of Dr. Milner as of the date hereof. Dr. Milner reserves the right to |
|
| June 6, 2023 |
Abcam in Focus Jonathan Milner www.abcamfocus.com June 2023 Exhibit 99.5 Abcam in Focus Jonathan Milner www.abcamfocus.com June 2023 Disclaimer 2 This document has been prepared by and on behalf of Dr. Jonathan Milner (Dr. Milner). Dr. Milner is providing this document for informational and discussion purposes only. The views expressed herein reflect the opinions of Dr. Milner as of the date hereof. Dr. Milner reserves the right to change or modify any opi |
|
| June 6, 2023 |
GB:ABCM / Abcam PLC / Milner Jonathan - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 4)* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 000380204 (CUSIP Number) Jonathan Mil |
|
| June 5, 2023 |
GB:ABCM / Abcam PLC / Milner Jonathan - SC 13D/A Activist Investment SC 13D/A 1 tm2317825-1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3)* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securit |
|
| June 5, 2023 |
Exhibit 99.4 GENERAL MEETING OF SHAREHOLDERS OF Abcam plc Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX United Kingdom (Registered in England & Wales under Company No. 03509322) PROXY STATEMENT DATED June 5, 2023 OF Jonathan Milner To Fellow Abcam Shareholders: This Proxy Statement and the accompanying BLUE Proxy Card are being furnished to shareholders (“Shareholders”) of |
|
| May 30, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address o |
|
| May 30, 2023 |
Exhibit 99.3 Jonathan Milner calls Extraordinary General Meeting to restore focus to Abcam on governance, execution, and cost control Proposal to appoint Jonathan Milner Executive Chairman of the Board Proposal to remove Peter Allen, Michael Baldock, and Sally Crawford as Directors of the Company Executive Chairman Milner intends to restore Abcam to the valuation it deserves CAMBRIDGE, England, 30 |
|
| May 30, 2023 |
GB:ABCM / Abcam PLC / Milner Jonathan - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 000380204 (CUSIP Number) Jonathan Mil |
|
| May 30, 2023 |
[signature on the following page] Exhibit 99.2 Abcam plc Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX United Kingdom Attn: Board of Directors Sent via e-mail at [email protected] and by post at the above address May 30, 2023 Re: Request to Convene a General Meeting of Abcam plc To the Board of Directors: In accordance with §§303 and 304 of the Companies Act 2006 (“CA 2006”), the undersigned, being the ho |
|
| May 30, 2023 |
ABCAM PLC (“Abcam” or “the Company”) Statement on calling an Extraordinary General Meeting Exhibit 99.1 30 May 2023 ABCAM PLC (“Abcam” or “the Company”) Statement on calling an Extraordinary General Meeting Cambridge, UK / Waltham, MA: Abcam plc (“Abcam,” “Company,” “Group”) (Nasdaq: ABCM), a global leader in the supply of life science research tools, notes that it has received a notice from Dr. Jonathan Milner seeking to require the Board of Directors to convene an Extraordinary Genera |
|
| May 18, 2023 |
GB:ABCM / Abcam PLC / Milner Jonathan - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1)* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 000380204 (CUSIP Number) Jonathan Mil |
|
| May 18, 2023 |
Exhibit 99.1 Jonathan Milner Announces That He is Taking Steps to Call an Extraordinary General Meeting of Abcam Shareholders Delivers Open Letter to Abcam shareholders Follows sustained period of operational underperformance since the start of 2020 and a track record of value destruction under the current Board and leadership team Critical for shareholders to have a platform to exert their right |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address of pr |
|
| May 17, 2023 |
ABCAM PLC Statement on potential Extraordinary General Meeting EX-99.1 Exhibit 99.1 17 May 2023 ABCAM PLC Statement on potential Extraordinary General Meeting Cambridge, UK/ Waltham, MA: Abcam plc (Nasdaq: ABCM), (“Abcam,” “Company,” “Group”) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today notes that its founder and former director Dr. Jonathan Milner has indicated he will take steps to call an extraordinary general meeting |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address of pr |
|
| May 17, 2023 |
ABCAM PLC (“Abcam” or “the Company”) Result of Annual General Meeting EX-99.1 Exhibit 99.1 17 May 2023 ABCAM PLC (“Abcam” or “the Company”) Result of Annual General Meeting Cambridge, UK/ Waltham, MA: Abcam plc (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces the voting results from the Annual General Meeting (the “AGM”) held today. A total of 196,862,506 shares representing 85.7% of Abcam’s issued and outstanding voting capita |
|
| May 4, 2023 |
Exhibit 99.1 4 May 2023 ABCAM PLC Business Update Cambridge, UK: Abcam plc (“Abcam,” “Company,” “Group”) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the following updates. As part of the five-year strategy set out in 2019, focusing on generating durable revenue growth, the Company invested to remove scalability constraints through critical investmen |
|
| May 4, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address o |
|
| May 1, 2023 |
GB:ABCM / Abcam PLC / Milner Jonathan - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 000380204 (CUSIP Number) Jonathan Milner Honey Hill Hous |
|
| April 13, 2023 |
6-K 1 d484402d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX Un |
|
| April 13, 2023 |
EX-99.1 Exhibit 99.1 13 April 2023 ABCAM PLC Trading Update Cambridge, UK: Abcam plc (“Abcam,” “Company,” “Group”) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the following preliminary trading update for the quarter ending 31 March 2023. First Quarter 2023 Period Estimated Reported Revenue Estimated Adjusted Operating Profit % First Quarter 2023 >£1 |
|
| March 30, 2023 |
EX-99.1 Exhibit 99.1 30 March 2023 ABCAM PLC (“Abcam” or “the Company”) Publication of 2022 Annual Report and Accounts and Notice of Annual General Meeting Cambridge, UK: Abcam plc (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following release on 20 March 2023 of its final results for the year ended 31 December 2022 on Form 20-F with the Securities |
|
| March 30, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address |
|
| March 30, 2023 |
EX-99.2 Exhibit 99.2 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action that you should take, you should immediately consult your stockbroker, bank manager, solicitor, accountant or other independent advisor authorised under the Financial Services and Markets Act 2000. If you have sold or otherwise transferred all of your Abcam plc shares, pl |
|
| March 20, 2023 |
Consent of PricewaterhouseCoopers LLP EX-15.1 Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-263945) and Form S-8 (Nos. 333-252514, 333-257893 and 333-263946) of Abcam plc of our report dated March 20, 2023 relating to the financial statements and the effectiveness of internal control over financial reporting, |
|
| March 20, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SEC |
|
| March 20, 2023 |
Principal Financial Officer Certification Pursuant to Section 302 of the Sarbanes Oxley Act of 2002. EX-12.2 Exhibit 12.2 CERTIFICATION I, Michael Baldock, Chief Financial Officer, certify that: 1. I have reviewed this annual report on Form 20-F of Abcam plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m |
|
| March 20, 2023 |
EX-2.3 Exhibit 2.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Abcam plc has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our ordinary shares, nominal value £0.002 per share. Our American Depositary Shares, or ADSs, are exempt from regi |
|
| March 20, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address |
|
| March 20, 2023 |
Principal Executive Officer Certification Pursuant to Section 906 of the Sarbanes Oxley Act of 2002. EX-13.1 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of Abcam plc (the “Company”) for the year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Se |
|
| March 20, 2023 |
EX-99.1 Exhibit 99.1 ABCAM PLC Final results for the year ended 31 December 2022 15% Reported Revenue Growth & 8% Constant Exchange Rate Revenue Growth: Demand for Abcam In-house Products Continues 20 March 2023, Cambridge, UK – Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its results for the year en |
|
| March 20, 2023 |
Principal Financial Officer Certification Pursuant to Section 906 of the Sarbanes Oxley Act of 2002. EX-13.2 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of Abcam plc (the “Company”) for the year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Se |
|
| March 20, 2023 |
Principal Executive Officer Certification Pursuant to Section 302 of the Sarbanes Oxley Act of 2002. EX-12.1 Exhibit 12.1 CERTIFICATION I, Alan Hirzel, Chief Executive Officer, certify that: 1. I have reviewed this annual report on Form 20-F of Abcam plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misle |
|
| March 10, 2023 |
ABCAM PLC Abcam to Report Full Year Results on Monday, March 20, 2023 EX-99.1 Exhibit 99.1 ABCAM PLC Abcam to Report Full Year Results on Monday, March 20, 2023 10, March 2023, Cambridge, UK—Abcam plc (Nasdaq: ABCM) (“Abcam” or the “Company”), a global leader in the supply of life science research tools, will report its results for the year ended 31 December 2022 at 7.00 a.m. ET on 20 March 2023. Following the announcement, the Company will host a live teleconferenc |
|
| March 10, 2023 |
GB:ABCM / Abcam PLC / Milner Jonathan - SC 13G Passive Investment SC 13G Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 000380204 (CUSIP Number) December |
|
| March 10, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address |
|
| February 14, 2023 |
GB:ABCM / Abcam PLC / HARDING LOEVNER LP - HARDING LOEVNER LP Passive Investment SC 13G/A 1 abcma121423.htm HARDING LOEVNER LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Abcam Plc (Name of Issuer) American Depositary Receipt (Title of Class of Securities) 000380204 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate b |
|
| February 10, 2023 |
GB:ABCM / Abcam PLC / Durable Capital Partners LP - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 abcam-sc13ga123122.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Abcam plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 000380204 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 6, 2023 |
ABCM / Abcam plc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Abcam PLC (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] |
|
| January 30, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Addre |
|
| January 30, 2023 |
EX-99.1 Exhibit 99.1 30 January 2023 ABCAM PLC Trading Update Cambridge, UK: Abcam plc (“Abcam”, “Company”, “Group”) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the following preliminary trading update for the year ending 31 December 2022. Abcam concluded the third year of its five-year growth plan by further building capabilities to drive long term |
|
| December 12, 2022 |
Abcam plc Update on AIM Delisting EX-99.1 Exhibit 99.1 Abcam plc Update on AIM Delisting 12 December 2022 CAMBRIDGE, UK – Abcam plc, AIM:ABC and Nasdaq: ABCM (“Abcam” or the ”Company”), a global leader in the supply of life science research tools, today provides a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM (the “AIM Delisting”), as originally announced on 17 October 2022. |
|
| December 12, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Addr |
|
| November 14, 2022 |
ABCAM PLC Result of General Meeting – Shareholders approve AIM Delisting Exhibit 99.1 ABCAM PLC Result of General Meeting ? Shareholders approve AIM Delisting 11 November 2022, Cambridge, UK ? Abcam plc (AIM: ABC; Nasdaq: ABCM) (?Abcam? or the ?Company?), a global leader in the supply of life science research tools, today announces that the resolution put to its General Meeting held today for the cancellation of the admission of its Ordinary Shares to trading on AIM wa |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address |
|
| October 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address o |
|
| October 17, 2022 |
Exhibit 99.2 THIS DOCUMENT AND THE ACCOMPANYING DOCUMENTS ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION. If you are in any doubt as to any aspect of the proposals referred to in this Document, please consult your stockbroker, bank manager, solicitor, accountant or other independent adviser. If you have sold or otherwise transferred all of your Ordinary Shares, please send this Document, toget |
|
| October 17, 2022 |
EX-99.3 4 d408355dex993.htm EX-99.3 Exhibit 99.3 Attendance Card Abcam plc – General Meeting Notice of availability Please note that, depending on your election, hard copies of Abcam plc’s Notice of General Meeting may not be enclosed. Both documents are, however, available on the Company’s website at corporate.abcam.com. If at any point you should wish to opt out of receiving documents and inform |
|
| October 17, 2022 |
Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, OR INTO OR FROM ANY JURISDICTION IN WHICH THE SAME WOULD BE A VIOLATION OF THE LAWS OF SUCH JURISDICTION. NEITHER THIS ANNOUNCEMENT, NOR ANYTHING CONTAINED HEREIN, SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER IN ANY JURISDICTION. ABCAM PLC |
|
| October 17, 2022 |
Exhibit 99.4 AIM DELISTING On July 20, 2022 Abcam plc (the ?Company? or ?Abcam?) announced the Company?s intention to cancel the admission of its Ordinary Shares to trading on AIM (the ?AIM Delisting?), subject to shareholder approval. The announcement can be found at: corporate.abcam.com. The shareholder circular can be found at: corporate.abcam.com. As set out in the expected timetable of events |
|
| September 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address |
|
| September 12, 2022 |
Exhibit 99.1 ABCAM PLC Interim results for the six-month period ended 30 June 2022 20% constant exchange rate revenue growth in H1: Demand for Abcam In-house Products Increases 12 September 2022, Cambridge, UK ? Abcam plc (Nasdaq: ABCM; AIM: ABC) (?Abcam?, the ?Group? or the ?Company?), a global leader in the supply of life science research tools, today announces its interim results for the six-mo |
|
| September 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address |
|
| September 12, 2022 |
ABCAM PLC Appointment of Non-Executive Director Exhibit 99.1 ABCAM PLC Appointment of Non-Executive Director 12 September 2022, Cambridge, UK ? Abcam plc (AIM: ABC; Nasdaq: ABCM) (?Abcam?, ?Company?), a global leader in the supply of life science research tools, is pleased to announce the appointment of Luba Greenwood as a non-executive Director with immediate effect. Luba?s experiences focus on business development and strategy. She is a veter |
|
| August 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address of |
|
| August 17, 2022 |
ABCAM PLC Abcam to Report Half Year Results on Monday, September 12, 2022 Exhibit 99.1 ABCAM PLC Abcam to Report Half Year Results on Monday, September 12, 2022 17, August 2022, Cambridge, UK - Abcam plc (Nasdaq: ABCM; AIM: ABC) (?Abcam? or the ?Company?), a global leader in the supply of life science research tools, will report its results for the 6-month period ended 30 June 2022 at 12.00 p.m. BST (7.00 a.m. EDT) on 12 September 2022. Following the announcement, the C |
|
| July 20, 2022 |
ABCAM PLC First Half Trading Update Exhibit 99.1 20 July 2022 ABCAM PLC First Half Trading Update Cambridge, UK: Abcam plc (?Abcam?, ?Company?, ?Group?) (AIM: ABC; Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the following trading update for the six-month period ending 30 June 2022. The Company will release its full results for the six-month period on 12 September 2022. The Group expect |
|
| July 20, 2022 |
6-K 1 d495477d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX Uni |
|
| May 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address of pr |
|
| May 18, 2022 |
ABCAM PLC (“Abcam” or the “Company”) Result of Annual General Meeting EX-99.1 2 d261694dex991.htm EX-99.1 Exhibit 99.1 For immediate release 18 May 2022 ABCAM PLC (“Abcam” or the “Company”) Result of Annual General Meeting Abcam plc (AIM: ABC; NASDAQ: ABCM), a global leader in the supply of life science research tools, announces that all resolutions put to its Annual General Meeting (the “AGM”) held today were passed. The Board is pleased that all resolutions have b |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A Amendment No. 1 (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| March 29, 2022 |
Exhibit 4.2 ABCAM PLC INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series. 5 Section 2.2. Establishment of |
|
| March 29, 2022 |
Exhibit 99.1 Rules of the Abcam Growth Plan Adopted by the board of directors on 10 September 2021 Expiry date 31 December 2024 Table of Contents 1. Definitions and Interpretation 2 2. Grant of Awards 4 3. Performance Condition 4 4. Restrictions on Transfer and Bankruptcy 5 5. Plan Limits 5 6. Reduction and Recovery 6 7. Vesting and Settlement 7 8. Taxation and Regulatory Issues 9 9. Cash Equivale |
|
| March 29, 2022 |
S-8 1 d314461ds8.htm S-8 Registration No. 333- As filed with the United States Securities and Exchange Commission on March 29, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Abcam plc (Exact name of registrant as specified in its charter) United Kingdom Not Applicable (State or other jurisdiction of incorp |
|
| March 29, 2022 |
Filed with the Securities and Exchange Commission on March 29, 2022 F-3ASR 1 d320264df3asr.htm F-3ASR Table of Contents Filed with the Securities and Exchange Commission on March 29, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Abcam plc (Exact name of registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into En |
|
| March 29, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Abcam plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, nominal value ?0 |
|
| March 29, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Abcam plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Ordinary shares, nominal value ?0. |
|
| March 17, 2022 |
ABCAM PLC (“Abcam” or the “Company”) Director/PDMR Shareholding Notification Exhibit 99.1 For immediate release 17 March 2022 ABCAM PLC (?Abcam? or the ?Company?) Director/PDMR Shareholding Notification Cambridge, UK: Abcam plc (Nasdaq: ABCM; AIM: ABC), a global leader in the supply of life science research tools, has been notified of the following dealings in Abcam?s shares by certain Directors of the Company as follows: ? Michael Baldock, Chief Financial Officer, purchas |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address of |
|
| March 14, 2022 |
Principal Executive Officer Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. EX-13.1 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of Abcam plc (the “Company”) for the year ended December 31, 2021 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Se |
|
| March 14, 2022 |
Principal Financial Officer Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. EX-13.2 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of Abcam plc (the “Company”) for the year ended December 31, 2021 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Se |
|
| March 14, 2022 |
Form of American Depositary Receipt (included in Exhibit 2.1) Exhibit 2.1 Execution Version DEPOSIT AGREEMENT by and among ABCAM PLC and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of October 26, 2020 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 ?ADS Record Date? 1 Section 1.2 ?Affiliate? 1 Section 1.3 ?American Depositary Receipt(s)?, ?ADR(s)? and ?Receipt(s)? 1 Sectio |
|
| March 14, 2022 |
Exhibit 99.1 Abcam Plc Results for the 12- and 18-month periods ended 31 December 2021 Growing demand for Abcam?s portfolio of in-house products drives calendar 2021 revenues up by 22% at constant exchange rates Acquisition of BioVision completed 26 October 2021 CAMBRIDGE, United Kingdom, March 14, 2022 (GLOBE NEWSWIRE) ? Abcam plc (Nasdaq: ABCM; AIM: ABC) (?Abcam?, the ?Group? or the ?Company?), |
|
| March 14, 2022 |
EX-2.3 3 d267980dex23.htm EX-2.3 Exhibit 2.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Abcam plc has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our ordinary shares, nominal value £0.002 per share. Our American Depositary Shares, or |
|
| March 14, 2022 |
Consent of PricewaterhouseCoopers LLP Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-257893 and 333-252514) of Abcam plc of our report dated March 14, 2022 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 20-F. /s/ Pricewaterho |
|
| March 14, 2022 |
Principal Financial Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. EX-12.2 Exhibit 12.2 CERTIFICATION I, Michael Baldock, Chief Financial Officer, certify that: 1. I have reviewed this annual report on Form 20-F of Abcam plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not m |
|
| March 14, 2022 |
Principal Executive Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. EX-12.1 Exhibit 12.1 CERTIFICATION I, Alan Hirzel, Chief Executive Officer, certify that: 1. I have reviewed this annual report on Form 20-F of Abcam plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misle |
|
| March 14, 2022 |
our Annual Report on Form 20-F, which was filed with the SEC on March 14, 2022; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address of |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address |
|
| February 28, 2022 |
ABCAM PLC Abcam to Report Full Year Results on Monday, March 14, 2022 EX-99.1 2 d289134dex991.htm EX-99.1 Exhibit 99.1 ABCAM PLC Abcam to Report Full Year Results on Monday, March 14, 2022 28 February 2022, Cambridge, UK - Abcam plc (Nasdaq: ABCM; AIM: ABC) (“Abcam ” or the “Company”), a global leader in the supply of life science research tools, will report its results for the 12- and 18- month periods ended 31 December 2021 at 12.00 p.m. GMT (8.00 a.m. EST) on 14 |
|
| February 14, 2022 |
GB:ABCM / Abcam PLC / HARDING LOEVNER LP - HARDING LOEVNER LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Abcam Plc (Name of Issuer) American Depositary Receipt (Title of Class of Securities) 000380204 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| February 7, 2022 |
GB:ABCM / Abcam PLC / Durable Capital Partners LP - AMENDMENT TO FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Abcam plc (Name of Issuer) Ordinary Shares, nominal value of ?0.002 per share (Title of Class of Securities) 000380204 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 4, 2022 |
GB:ABC / Abcam PLC / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Abcam PLC (Name of Issuer) Common Stock (Title of Class of Securities) G0060R118 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| January 27, 2022 |
Exhibit 99.1 27 January 2022 ABCAM PLC Trading Update Cambridge, UK: Abcam plc (?Abcam?, ?Company?, ?Group?) (AIM: ABC; Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the following trading update ahead of reporting its financial results in March: The Group expects to report total revenues for the 12 months ended 31 December 2021 of approximately ?315 mi |
|
| January 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address o |
|
| December 3, 2021 |
ABCAM PLC Update on 2021 General Meeting Resolution Vote Exhibit 99.1 ABCAM PLC Update on 2021 General Meeting Resolution Vote 2 December 2021, Cambridge, UK - In accordance with the requirement of Provision 4 of the UK Corporate Governance Code (the ?Code?), Abcam plc (?Abcam?, ?the Company? or ?the Group?) (AIM LSE: ABC; Nasdaq: ABCM), is providing an update in response to the voting outcomes on the proposals for i) the Remuneration Policy and ii) the |
|
| December 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address |
|
| November 12, 2021 |
ABCAM PLC (“Abcam” or the “Company”) Issue of Equity and Director/PDMR Shareholding Notification Exhibit 99.1 For immediate release 10 November 2021 ABCAM PLC (?Abcam? or the ?Company?) Issue of Equity and Director/PDMR Shareholding Notification Abcam plc (AIM: ABC, the ?Group?) announces that it has made an application for the admission to trading on AIM of 1,784,189 ordinary shares of 0.2 pence each in the Company (the ?New Ordinary Shares?). These New Ordinary Shares have been issued to sa |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address |
|
| October 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address o |
|
| October 27, 2021 |
ABCAM PLC Abcam Completes Acquisition of BioVision EX-99.1 2 d169156dex991.htm EX-99.1 Exhibit 99.1 ABCAM PLC Abcam Completes Acquisition of BioVision October 27, 2021, Cambridge, UK—Abcam plc (“Abcam”, “the Company” or “the Group”) (AIM LSE: ABC; Nasdaq: ABCM), a global leader in the supply of life science research tools, today announces that is has completed its acquisition of BioVision, Inc (“BioVision”) from Boai NKY Medical Holdings Ltd. (“NK |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address |
|
| September 13, 2021 |
Exhibit 99.1 ABCAM PLC Interim results for the six and 12-month periods ended June 30, 2021 29% Constant Currency Revenue Growth in H2 as Lab Activity Gradually Recovers and Demand for Abcam In-house Products Increases September 13, 2021, Cambridge, UK ? Abcam plc (Nasdaq: ABCM; AIM: ABC) (?Abcam?, the ?Group? or the ?Company?), a global leader in the supply of life science research tools, today a |
|
| September 1, 2021 |
ABCAM PLC Filing of Transition Report on Form 20-F and Notice of Results Exhibit 99.1 ABCAM PLC Filing of Transition Report on Form 20-F and Notice of Results 1 September 2021, Cambridge, UK ? Abcam plc (AIM: ABC; Nasdaq: ABCM) (?Abcam?, ?Company?, or the ?Group?) has today filed with the U.S. Securities and Exchange Commission a transition report on Form 20-F for the six-month period from 1 July 2020 to 31 December 2020 in relation to the Company?s change of fiscal ye |
|
| September 1, 2021 |
Principal Financial Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. EX-12.2 Exhibit 12.2 CERTIFICATIONS I, Michael Baldock, Chief Financial Officer, certify that: 1. I have reviewed this transition report on Form 20-F of Abcam plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, |
|
| September 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address |
|
| September 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| September 1, 2021 |
Principal Executive Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Exhibit 12.1 CERTIFICATIONS I, Alan Hirzel, Chief Executive Officer, certify that: 1. I have reviewed this transition report on Form 20-F of Abcam plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadi |
|
| September 1, 2021 |
Principal Executive Officer Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. EX-13.1 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Transition Report on Form 20-F of Abcam plc (the “Company”) for the transition period ended December 31, 2020 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15 |
|
| September 1, 2021 |
Principal Financial Officer Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Transition Report on Form 20-F of Abcam plc (the ?Company?) for the transition period ended December 31, 2020 (the ?Report?) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address of |
|
| August 13, 2021 |
ABCAM PLC (“Abcam” or the “Company”) Directorate Change Appointment of Non-Executive Director Exhibit 99.1 ABCAM PLC (?Abcam? or the ?Company?) Directorate Change Appointment of Non-Executive Director 13 August 2021, Cambridge, UK ? Abcam plc (AIM: ABC; Nasdaq: ABCM) (?Abcam?, ?Company?), a global leader in the supply of life science research tools, is pleased to announce the appointment of Sally W. Crawford as a non-executive Director with immediate effect. Sally will join the Remuneratio |
|
| August 2, 2021 |
ABCAM PLC Abcam to Acquire BioVision for $340 million EX-99.1 2 d179569dex991.htm EX-99.1 Exhibit 99.1 ABCAM PLC Abcam to Acquire BioVision for $340 million 2 August 2021, Cambridge, UK – Abcam plc (“Abcam”, “the Company” or “the Group”) (AIM LSE: ABC; Nasdaq: ABCM), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire BioVision, Inc. (“BioVision”), a wholly owned sub |
|
| August 2, 2021 |
6-K 1 d179569d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX U |
|
| July 14, 2021 |
Abcam Plc Profitable Growth Incentive Plan Exhibit 99.1 Rules of the Abcam plc Profitable Growth Incentive Plan Approved by shareholders on 1 July 2021 Approved by the board of directors on 1 June 2021 Expiry date 31 December 2024 Table of Contents 1. Definitions and Interpretation 2 2. Grant of Awards 5 3. Performance Condition 6 4. Restrictions on Transfer and Bankruptcy 6 5. Individual Limit 7 6. Plan Limits 7 7. Reduction and Recovery |
|
| July 14, 2021 |
Registration No. 333- As filed with the United States Securities and Exchange Commission on July 14, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Abcam plc (Exact name of registrant as specified in its charter) United Kingdom Not Applicable (State or other jurisdiction of incorporation or organization) ( |
|
| July 1, 2021 |
ABCAM PLC Pre-Close Trading Update Exhibit 99.1 1 July 2021 ABCAM PLC Pre-Close Trading Update Cambridge, UK: Abcam plc (?Abcam?, ?Company?, ?Group?) (AIM: ABC; Nasdaq: ABCM), a global leader in the supply of life science research tools, provides the following pre-close trading update for the six-month period ended 30 June 2021 (the ?Period?) ahead of its General Meeting to be held this afternoon. As previously announced, the Compa |
|
| July 1, 2021 |
ABCAM PLC Result of General Meeting Exhibit 99.1 1 July 2021 ABCAM PLC Result of General Meeting Abcam plc (AIM: ABC; NASDAQ: ABCM), a global leader in the supply of life science research tools, announces that all resolutions put to its General Meeting (the ?General Meeting?) held this afternoon were passed. The Board is pleased that all resolutions have been approved by shareholders and notes that a minority of shareholders opposed |
|
| July 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address of p |
|
| July 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address of p |
|
| June 2, 2021 |
EX-99.1 2 d167136dex991.htm EX-99.1 Exhibit 99.1 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action that you should take, you should immediately consult your stockbroker, bank manager, solicitor, accountant, or other independent advisor authorised under the Financial Services and Markets Act 2000. If you have sold or otherwise transferred all |
|
| June 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address of p |
|
| June 2, 2021 |
APPENDIX 1 2021 Directors’ Remuneration Policy (the ‘Policy’) Exhibit 99.2 Notice of General Meeting 2021 NOTICE is hereby given that a General Meeting of Abcam plc (Company) will be held on 1 July 2021 at Discovery Drive, Cambridge Biomedical Campus, Cambridge CB2 0AX at 2.00 pm to consider and, if thought fit, pass the following resolutions. All resolutions will be proposed as ordinary resolutions, save for resolutions 4 to 6 (inclusive) which will be prop |
|
| May 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address of pr |
|
| May 19, 2021 |
ABCAM PLC (“Abcam” or “the Company”) Directorate Change Exhibit 99.1 19 May 2021 ABCAM PLC (?Abcam? or ?the Company?) Directorate Change Abcam plc announces that, after seven years with the Company, Lady Louise Patten has retired from her roles as Non-executive Director, Senior Independent Director and Chair of the Remuneration Committee. Giles Kerr, who joined the Board in 2018, will become Senior Independent Director with immediate effect. Mara Aspin |
|
| March 12, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address of |
|
| March 12, 2021 |
Exhibit 99.1 For immediate release 12 March 2021 ABCAM PLC (?Abcam? or the ?Company?) Director/PDMR Shareholding Notification 1 Details of the person discharging managerial responsibilities/person closely associated a) Name Mr Marc Perkins 2 Reason for the notification a) Position/status General Counsel and Company Secretary b) Initial notification /Amendment Initial notification 3 Details of the |
|
| March 11, 2021 |
Regulatory News Service Announcement dated March 10, 2021 (Replacement) Exhibit 99.1 For immediate release 10 March 2021 ABCAM PLC (?Abcam? or the ?Company?) Director/PDMR Shareholding Notification Cambridge, UK: Abcam plc (Nasdaq: ABCM; AIM: ABC), a global leader in the supply of life science research tools, has been notified of the following dealings in Abcam?s shares by certain Directors of the Company as follows: ? Alan Hirzel, Chief Executive Officer, purchased 2 |
|
| March 11, 2021 |
Current Report of Foreign Issuer - 6-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United |
|
| March 10, 2021 |
ABCAM PLC (“Abcam” or the “Company”) Director/PDMR Shareholding Notification EX-99.1 2 d141443dex991.htm EX-99.1 Exhibit 99.1 10 March 2021 ABCAM PLC (“Abcam” or the “Company”) Director/PDMR Shareholding Notification Cambridge, UK: Abcam plc (Nasdaq: ABCM; AIM: ABC), a global leader in the supply of life science research tools, has been notified of the following dealings in Abcam’s shares by certain Directors of the Company as follows: • Alan Hirzel, Chief Executive Office |
|
| March 10, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address of |
|
| March 8, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-39633 Abcam plc (Translation of registrant?s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Address of |
|
| March 8, 2021 |
EX-99.1 2 d146327dex991.htm EX-99.1 Exhibit 99.1 ABCAM PLC Interim results 8.3% constant currency revenue growth in H1 as customers gradually return to labs 8 March 2021, Cambridge, UK – Abcam plc (Nasdaq: ABCM; AIM: ABC) (“Abcam”, the “Group” or the “Company”), a global leader in the supply of life science research tools, today announces its interim results for the six month period ended 31 Decem |
|
| February 26, 2021 |
Current Report of Foreign Issuer - 6-K 6-K 1 d143267d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX |
|
| February 26, 2021 |
ABCAM PLC Abcam to Report Interim Results on Monday, March 8, 2021 Exhibit 99.1 ABCAM PLC Abcam to Report Interim Results on Monday, March 8, 2021 Cambridge, UK, February 26, 2021 (GlobeNewsWire) ? Abcam plc (Nasdaq: ABCM, AIM: ABC), a global leader in the supply of life science research tools, will report its Interim Results for the six-month period ended 31 December 2020 at 12.00 p.m. GMT (7.00 a.m. EST) on Monday, March 8, 2021. Following the announcement, the |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) (Amendment No. |
|
| January 28, 2021 |
S-8 As filed with the United States Securities and Exchange Commission on January 28, 2021 Registration No. |
|
| January 28, 2021 |
ABCAM PLC Appointment of Non-Executive Directors EX-99.1 Exhibit 99.1 ABCAM PLC Appointment of Non-Executive Directors 28 January 2021, Cambridge, UK – Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam”), a global leader in the supply of life science research tools, is delighted to announce the appointments of Bessie Lee and Mark Capone as non-executive Directors with immediate effect. Both Bessie and Mark bring extensive and complementary executive an |
|
| January 28, 2021 |
Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2021 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Addre |
|
| January 11, 2021 |
Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2021 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Addre |
|
| January 11, 2021 |
EX-99.1 2 d83159dex991.htm EX-99.1 Exhibit 99.1 ABCAM PLC Half Year Trading Update Abcam returns to growth in first half with over 8% increase in constant currency revenue 11 January, 2021, Cambridge, UK—Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam”), a global leader in the supply of life science research tools, announces the following unaudited trading update ahead of reporting its results on 8 Mar |
|
| December 22, 2020 |
Abcam To Announce H1 Trading Update and Host Conference Call and Webcast on 11 January 2020 EX-1 Exhibit 1 Abcam To Announce H1 Trading Update and Host Conference Call and Webcast on 11 January 2020 Cambridge, UK, December 21, 2020 – Abcam plc (LSE: ABC; Nasdaq: ABCM, “Abcam”) announces that it will release an unaudited trading update ahead of its results for the six months ended 31 December 2020 at 1200 GMT on Monday 11 January 2021. |
|
| December 22, 2020 |
Abcam plc to present at the 39th Annual J.P. Morgan Healthcare Conference EX-2 Exhibit 2 Abcam plc to present at the 39th Annual J.P. Morgan Healthcare Conference Cambridge, UK, December, 21, 2020 – Abcam plc (LSE: ABC; Nasdaq: ABCM, “Abcam”) announces that Alan Hirzel, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021, at 1400 Eastern Standard Time (1900 GMT). A live audio webcast of the presentatio |
|
| December 22, 2020 |
Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2020 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Addr |
|
| December 7, 2020 |
Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2020 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Addr |
|
| December 7, 2020 |
ABCAM PLC (“Abcam” or the “Company”) Result of Annual General Meeting EX-99.1 Exhibit 99.1 For immediate release 4 December 2020 ABCAM PLC (“Abcam” or the “Company”) Result of Annual General Meeting Abcam plc (AIM: ABC; NASDAQ: ABCM), a global leader in the supply of life science research tools, announces that all resolutions put to its Annual General Meeting (the “AGM”) held today were passed. Full details of the poll results are available at www.abcamplc.com. For |
|
| November 4, 2020 |
Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Addr |
|
| November 4, 2020 |
EX-99.1 Exhibit 99.1 For immediate release 04 November 2020 ABCAM PLC (“Abcam” or the “Company”) Director/PDMR Shareholding Notification 1 Details of the person discharging managerial responsibilities/person closely associated a) Name Mr Alan Hirzel 2 Reason for the notification a) Position/status Chief Executive Officer b) Initial notification /Amendment Initial Notification 3 Details of the issu |
|
| November 3, 2020 |
Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 001-39633 Abcam plc (Translation of registrant’s name into English) Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom (Addr |
|
| November 3, 2020 |
EX-99.1 Exhibit 99.1 3 November 2020 ABCAM PLC (“Abcam” or “the Company”) Publication of 2020 Annual Report and Accounts and Notice of Annual General Meeting Cambridge, UK: Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following release on 14 September 2020 of its final results for the year ended 30 June 2020, the Abcam plc Annua |
|
| November 3, 2020 |
EX-99.2 Exhibit 99.2 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action that you should take, you should immediately consult your stockbroker, bank manager, solicitor, accountant or other independent advisor authorised under the Financial Services and Markets Act 2000. If you have sold or otherwise transferred all of your Abcam plc shares, pl |
|
| November 3, 2020 |
ABCAM PLC (“Abcam” or “the Company”) Consultation on 2020 LTIP Awards EX-99.3 4 d47641dex993.htm EX-99.3 Exhibit 99.3 3 November 2020 ABCAM PLC (“Abcam” or “the Company”) Consultation on 2020 LTIP Awards Cambridge, UK: Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following consultation with shareholders on the Group’s overall LTIP structure and performance framework, including proposed changes for |
|
| October 22, 2020 |
8,945,218 American Depositary Shares Representing 8,945,218 ordinary shares Abcam plc 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-249263 and 333-249592 PROSPECTUS 8,945,218 American Depositary Shares Representing 8,945,218 ordinary shares Abcam plc This is the initial public offering of Abcam plc in the United States. We are offering 8,945,218 American Depositary Shares, or ADSs, with each ADS representing the right to receive 8,945,218 ordinary s |
|
| October 21, 2020 |
F-1/A As filed with the Securities and Exchange Commission on October 21, 2020. Registration No. 333-249263 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Abcam plc (Exact Name of Registrant as Specified in its Charter) United Kingdom 2836 Not Applicable (State or Other Jurisdiction of Inco |
|
| October 21, 2020 |
53rd at Third 885 Third Avenue New York, New York 10022-4834 Tel: +1.212.906.1200 Fax: +1.212.751.4864 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris October 21, 2020 Dubai Riyadh D?sseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Tokyo Madrid |
|
| October 21, 2020 |
F-1/A As filed with the Securities and Exchange Commission on October 21, 2020. Registration No. 333-249263 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Abcam plc (Exact Name of Registrant as Specified in its Charter) United Kingdom 2836 Not Applicable (State or Other Jurisdiction of Inco |
|
| October 21, 2020 |
F-1MEF 1As filed with the U.S. Securities and Exchange Commission on October 21, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Abcam plc (Exact Name of Registrant as Specified in its Charter) Not Applicable (Translation of Registrant’s Name into English) United Kingdom 2836 Not Ap |
|
| October 19, 2020 |
Form 8-A filed on October 19, 2020 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Abcam plc (Exact name of Registrant as Specified in its Charter) United Kingdom Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identificatio |
|
| October 19, 2020 |
Form of Underwriting Agreement EX-1.1 Exhibit 1.1 ABCAM PLC [•] AMERICAN DEPOSITARY SHARES REPRESENTING [•] ORDINARY SHARES, NOMINAL VALUE £0.002 PER SHARE UNDERWRITING AGREEMENT [•], 2020 Morgan Stanley & Co. LLC BofA Securities, Inc. as Representatives of the several Underwriters listed in Schedule I hereto c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o BofA Securities, Inc. One Bryant Park New York, |
|
| October 19, 2020 |
Abcam plc Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom Abcam plc Discovery Drive Cambridge Biomedical Campus Cambridge, CB2 0AX United Kingdom October 19, 2020 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| October 19, 2020 |
October 19, 2020 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| October 19, 2020 |
Form of American Depositary Receipt (included in Exhibit 4.1) EX-4.1 Exhibit 4.1 Execution Version DEPOSIT AGREEMENT by and among ABCAM PLC and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [date], 2020 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 “ADS Record Date” 1 Section 1.2 “Affiliate” 1 Section 1.3 “American Depositary Receipt(s)”, “ADR(s)” and “Receipt(s)” 2 Sec |
|
| October 19, 2020 |
F-1/A Table of Contents As filed with the Securities and Exchange Commission on October 19, 2020. |
|
| October 2, 2020 |
Company Share Option Plan 2009 EX-10.5 Exhibit 10.5 ABCAM PLC RULES OF THE ABCAM PLC COMPANY SHARE OPTION PLAN 2009 Approved by a board on: 5th November 2009 Approved by HM Revenue & Customs on: 6th November 2009 HM Revenue & Customs reference no: X105353 PricewaterhouseCoopers LLP 1 Embankment Place London WC2N 6RH Tel: 020 7583 5000 Fax: 020 7822 4652 Ref: MP/OA/SH/EP6 CONTENTS Rule Page Number 1. INTERPRETATION 1 1.1. Defini |
|
| October 2, 2020 |
53rd at Third 885 Third Avenue New York, New York 10022-4834 Tel: +1.212.906.1200 Fax: +1.212.751.4864 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris Dubai Riyadh D?sseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Tokyo Madrid Washington, D.C. |
|
| October 2, 2020 |
EX-10.2 Exhibit 10.2 AbShare Approved by the Remuneration Committee on behalf of the Board of Directors on 4 September 2018 CONTENTS 1. DEFINITIONS AND INTERPRETATION 3 2. INVITATION 5 3. ENROLING IN THE PLAN 6 4. GRANT OF AWARDS 6 5. PERFORMANCE CONDITION 6 6. PLAN LIMITS 6 7. VESTING OF THE PURCHASED SHARE AWARD 7 8. VESTING OF THE MATCHING SHARE AWARD 7 9. THE HOLDING PERIOD 7 10. TAXATION AND |
|
| October 2, 2020 |
Articles of Association of the Registrant EX-3.1 Exhibit 3.1 Company No. 3509322 THE COMPANIES ACT 2006 A PUBLIC COMPANY LIMITED BY SHARES ARTICLES OF ASSOCIATION of ABCAM PLC (adopted by special resolution passed on 1st November 2010) Eversheds LLP Tel 0845 497 9797 One Wood Street Fax +44 (0) 20 7919 4919 London Int +44 (0) 20 7919 4500 EC2V 7WS www.eversheds.com CONTENTS Article Page PRELIMINARY 1 1 DISAPPLICATION OF TABLE A 1 2 INTERP |
|
| October 2, 2020 |
List of subsidiaries of the Registrant EX-21.1 Exhibit 21.1 Subsidiaries of the Registrant Legal Name of Subsidiary Jurisdiction of Organization Abcam (US) Ltd. United Kingdom Abcam US Group Holdings Inc. United States Abcam Trading (Shanghai) Co. Ltd. China Epitomics Inc. United States |
